N Engl J Med 2024;390:1394-407
Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L
A 300-pound patient starts at 0.25 mg semaglutide, the same as a 180-pound patient
Some important clinical considerations include: People with pre-existing diabetic retinopathy should be monitored closely, as rapid improvement in blood glucose control with semaglutide has been associated with temporary worsening of retinopathy complications [15] [16] GLP-1 receptor agonists may cause a modest increase in heart rate These medications should not be used in combination with DPP-4 inhibitors, as recommended by NICE NICE guidance recommends regular monitoring of HbA1c and body weight to assess treatment efficacy, with continuation of therapy dependent upon achieving meaningful clinical benefits within the first six months of treatment
No-DAC + ipamorelin in the same syringe is the standard starting point
GLP-1 injections not only assist in managing appetite but also improve overall metabolic health, making them a valuable tool for achieving and maintaining a healthier weight